Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/13/25
Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/04/25
Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific AntibodyGlobeNewsWire • 01/14/25
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock UpsideBenzinga • 01/07/25
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast CancerGlobeNewsWire • 09/16/24
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/13/24
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 AntibodyGlobeNewsWire • 08/01/24
Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/10/24
Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/21/24
Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/13/23
Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual MeetingGlobeNewsWire • 11/06/23
After Plunging -18.52% in 4 Weeks, Here's Why the Trend Might Reverse for Instil Bio, Inc. (TIL)Zacks Investment Research • 08/31/23
Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/14/23
Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual ConferenceGlobeNewsWire • 06/26/23
Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/11/23